Reneo Pharmaceuticals Stock Today
| RPHM Stock | USD 1.69 0.05 2.87% |
Performance4 of 100
| Odds Of DistressLess than 24
|
Reneo Pharmaceuticals is selling at 1.69 as of the 23rd of April 2024; that is -2.87 percent down since the beginning of the trading day. The stock's lowest day price was 1.65. Reneo Pharmaceuticals has about a 24 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Reneo Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of March 2024 and ending today, the 23rd of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of April 2021 | Category Healthcare | Classification Health Care |
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company was incorporated in 2014 and is headquartered in Irvine, California. The company has 33.42 M outstanding shares of which 2.92 M shares are at this time shorted by private and institutional investors with about 17.8 trading days to cover. More on Reneo Pharmaceuticals
Moving against Reneo Stock
| 0.69 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.62 | ANAB | AnaptysBio Financial Report 9th of May 2024 | PairCorr |
| 0.56 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.56 | GNTA | Genenta Science SpA Report 24th of April 2024 | PairCorr |
| 0.55 | REPL | Replimune Group Financial Report 16th of May 2024 | PairCorr |
| 0.55 | ALKS | Alkermes Plc Financial Report 24th of April 2024 | PairCorr |
| 0.52 | PCRX | Pacira Pharmaceuticals Financial Report 1st of May 2024 | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Financial Report 9th of May 2024
Reneo Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Reneo Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Reneo Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Gregory Flesher | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Reneo Pharmaceuticals report their recommendations after researching Reneo Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Reneo Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Reneo Pharmaceuticals. The Reneo consensus assessment is calculated by taking the average forecast from all of the analysts covering Reneo Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Reneo Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Reneo Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Reneo Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Reneo Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Reneo Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Reneo Pharmaceuticals' financial leverage. It provides some insight into what part of Reneo Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Reneo Pharmaceuticals (RPHM) is traded on NASDAQ Exchange in USA. It is located in 18575 Jamboree Road, Irvine, CA, United States, 92612 and employs 8 people. Reneo Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 56.48 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Reneo Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Reneo Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Reneo Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 33.42 M outstanding shares of which 2.92 M shares are at this time shorted by private and institutional investors with about 17.8 trading days to cover.
Reneo Pharmaceuticals currently holds about 126.85 M in cash with (63.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.18, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Reneo Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationReneo Pharmaceuticals owns a total of 33.42 Million outstanding shares. The majority of Reneo Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Reneo Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Reneo Pharmaceuticals. Please pay attention to any change in the institutional holdings of Reneo Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Reneo Ownership Details
Reneo Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Reneo Pharmaceuticals jumping above the current price in 90 days from now is about 22.55%. The Reneo Pharmaceuticals probability density function shows the probability of Reneo Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Reneo Pharmaceuticals has a beta of 0.0226 indicating as returns on the market go up, Reneo Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Reneo Pharmaceuticals will be expected to be much smaller as well. Additionally, reneo Pharmaceuticals has an alpha of 0.0451, implying that it can generate a 0.0451 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Reneo Pharmaceuticals to move above the current price in 90 days from now is about 22.55 (This Reneo Pharmaceuticals probability density function shows the probability of Reneo Stock to fall within a particular range of prices over 90 days) .
Reneo Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Reneo Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Reneo Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Reneo Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Renaissance Technologies Corp | 2023-12-31 | 400.4 K | |
| Vestal Point Capital Lp | 2023-12-31 | 400 K | |
| Geode Capital Management, Llc | 2023-12-31 | 339.5 K | |
| State Street Corporation | 2023-12-31 | 247.4 K | |
| Two Sigma Investments Llc | 2023-12-31 | 182.5 K | |
| Millennium Management Llc | 2023-12-31 | 158.9 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 129.6 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 124.9 K | |
| Boothbay Fund Management, Llc | 2023-12-31 | 119.6 K | |
| Nea Management Company, Llc | 2023-12-31 | 4.8 M | |
| The Carlyle Group Inc | 2023-12-31 | 2.7 M |
Reneo Pharmaceuticals Historical Income Statement
Reneo Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Reneo's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Reneo Pharmaceuticals revenue and expense. Reneo Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Reneo Pharmaceuticals' Cost Of Revenue is very stable compared to the past year. As of the 23rd of April 2024, Reconciled Depreciation is likely to grow to about 178.5 K, while Interest Income is likely to drop about 24.8 K. View More FundamentalsReneo Stock Against Markets
Picking the right benchmark for Reneo Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Reneo Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Reneo Pharmaceuticals is critical whether you are bullish or bearish towards Reneo Pharmaceuticals at a given time. Please also check how Reneo Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Reneo Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
Reneo Pharmaceuticals Corporate Management
Elected by the shareholders, the Reneo Pharmaceuticals' board of directors comprises two types of representatives: Reneo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reneo. The board's role is to monitor Reneo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Reneo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reneo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alejandro MD | Chief Officer | Profile | |
| Ashley JD | Chief Officer | Profile | |
| Wendy MBA | Consultant | Profile | |
| Vineet Jindal | Consultant | Profile | |
| Michael Cruse | Chief Officer | Profile | |
| Jennifer Lam | Principal Officer | Profile |
How to buy Reneo Stock?
Before investing in Reneo Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Reneo Pharmaceuticals. To buy Reneo Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Reneo Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Reneo Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Reneo Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Reneo Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Reneo Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Reneo Stock please use our How to Invest in Reneo Pharmaceuticals guide.
Already Invested in Reneo Pharmaceuticals?
The danger of trading Reneo Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Reneo Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Reneo Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Reneo Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Reneo Pharmaceuticals is a strong investment it is important to analyze Reneo Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reneo Pharmaceuticals' future performance. For an informed investment choice regarding Reneo Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reneo Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in Reneo Stock, please use our How to Invest in Reneo Pharmaceuticals guide.Note that the Reneo Pharmaceuticals information on this page should be used as a complementary analysis to other Reneo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Reneo Stock analysis
When running Reneo Pharmaceuticals' price analysis, check to measure Reneo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reneo Pharmaceuticals is operating at the current time. Most of Reneo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reneo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reneo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reneo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Reneo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reneo Pharmaceuticals. If investors know Reneo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reneo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.52) | Return On Assets (0.48) | Return On Equity (0.82) |
The market value of Reneo Pharmaceuticals is measured differently than its book value, which is the value of Reneo that is recorded on the company's balance sheet. Investors also form their own opinion of Reneo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reneo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reneo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reneo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reneo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reneo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reneo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.